Radiobiology of LDR, HDR, PDR and VLDR Brachytherapy - GEC-ESTRO Handbook of Brachytherapy

20 / 21

THE GEC ESTROHANDBOOKOF BRACHYTHERAPY | Part I: The Basics of Brachytherapy
Version 1 - 22/10/2015
Radiobiology of LDR, HDR, PDR and VLDR Brachytherapy 20
89. Mazeron JJ, Ardiet JM, Haie-Meder, C ,Kovacs G ,Levendag P, Peiffert D, Polo
A, Rovirosa A, Strnad V. GEC-ESTRO recommendations for brachytherapy
for head and neck squamous cell carcinoma. Radiother Oncol 2009: 91, 150-
156
90. Nag S, Cano E.R., Demanes D.J., et al..The American Brachytherapy Society
recommendations for high-dose-rate brachytherapy for head and neck carci-
noma. Int J Radiat Oncol Biol Phys, 2001, 50: 1190–1198
91. Newman G. Increased morbidity following the introduction of remote af-
terloading with increased dose rate for cancer of the cervix. Radiother Oncol
1996; 39: 97-103.
92. Nose T, Koizumi M, Nisjiyama K. High-dose-rate interstitial brachytherapy
for oropharyngeal carcinoma: results of 83 lesions in 82 patients. Int.J. Radiat.
Oncol. Biol. Phys. 2004 59 (4) 983-991
93. Orton CG, Seyedsadr M, Sommay A. Comparison of high and low dose rate
remote afterloading for cervix cancer and the importance of fractionation. Int
J Radiat Oncol Biol Phys 1991; 21: 1425-34.
94. Patel FD, Sharma SC, Negi PS, et al. Low dose rate versus high dose rate BT
in the treatment of carcinoma of the uterine cervix: a clinical trial. Int J Radiat
Oncol Biol Phys 1994; 28: 335-41.
95. Peiffert D, Castelain B, Thomas L, Ardiet JM, Baillet F, Mazeron JJ. Pulsed dose
rate BT in head and neck cancers. Feasibility study of a French cooperative
group. Radiother Oncol 2001; 58: 71-5.
96. Perez CA, Grigsby PW, Castro-Vita H, Lockett MA.therapy. Int J Radiat Oncol
Biol Phys. 1995 ;32(5):1275-88
97. Pernot M, Malissard L, Hoffstetter S, et al. The study of tumoral, radiobio-
logical, and general health factors that influence results and complications in
a series of 448 oral tongue carcinomas treated exclusively by irradiation. Int J
Radiat Oncol Biol Phys 1994; 29: 673-9.
98. Pernot M, Malissard L, Hoffstetter S, et al. Influence of tumoral, radiobiologi-
cal and general factors on local control and survival of a series of 361 tumors
of the velotonsillar area treated by exclusive irradiation (external beam irradi-
ation + BT or BT alone). Int J Radiat Oncol Biol Phys 1994; 30: 1051-7.
99. Pernot M, Luporsi E, Hoffsteitter S, et al. Complications following irradiation
for cancers of the oral cavity and the oropharynx (in a series of 1134 patients).
Int J Radiat Oncol Biol Phys 1997; 37: 577-85.
100. Petereit DG, Sarkaria JN, Potter DM, Schrink JC. High-dose-rate versus low-
dose-rate BT in the treatment of cervical cancer: analysis of tumor recurrence.
The University of Wisconsin experience. Int J Radiat Oncol Biol Phys 1999; 45:
1267-74.
101. Petereit DG, Sarkaria JN, Chappell R, Fowler JF, Hartmann TJ, Kinsella TJ,
Stitt JA, Thomadsen BR, Buchler DA.The adverse effect of treatment prolon-
gation in cervical carcinoma.Int J Radiat Oncol Biol Phys. 1995; 32(5):1301-7.
102. Pierquin B, Chassagne D, Baillet F, Paine C. Clinical observations on the time
factor in interstitial radiotherapy using iridium 192. Clin Radiol 1973; 24: 506-
9.
103. Polgar C, Orosz Z, Fodor J, Fodor J, Sulyok Z, JToth , et al. The effect of high-
dose rate brachytherapy and electron boost on local control and side effects af-
ter breast conserving surgery: first results of the randomized Budapest breast
boost trial Radiother Oncol, 2001: 60 (Suppl 1) , p. 10 [abstract]
104. Poortmans P, Bartelink H, Horiot JC, et al. The influence of the boost tech-
nique on local control in breast conserving treatment in the EORTC ‘‘boost
versus no boost” randomised trial. Radiother Oncol 2004; 72:25–33.
105. Resch A, Poetter R, Van Limbergen E, Biber E, Klein T, Fellner C, et al. l.
Long term results (10 years) of intensive breast conserving therapy including
a high-dose and large-volume interstitial BT boost (LDR/HDR) for T1-T2
breast cancer. Radiother Oncol 2002
106. Roed H, Engelholm SA, Svendsen LB, et al. Pulsed dose rate (PDR) BT of anal
carcinoma. Radiother Oncol 1996; 41: 131-4.
107. Sarin R, Dinshaw K, Shrivastava SK, et al. Therapeutic factors influencing the
cosmetic outcome and late complications in the conservative management of
early breast cancer. Int J Radiat Oncol Biol Phys 1993; 30: 285-92.
108. Scalliet P, Landuyt W, van der Schueren E. Effects of decreasing the dose rate
of irradiation on the mouse lip mucosa: comparison with fractionated irradi-
ations. Radiother Oncol 1987; 10: 39-47.
109. Scalliet P, Landuyt W, van der Schueren E. Kinetics of repair: its influence in
low dose rate irradiations. Radiother Oncol 1988; 11: 249-51.
110. Scalliet P, Landuyt W, van der Schueren E. Repair kinetics as a determining for
late tolerance of central nervous system to low dose rate irradiation. Radiother
Oncol 1989; 14: 345-53.
111. Scalliet P, Wambersie A. Which RBE for iodine 125 BT? Radiother Oncol 1988.
112. Shigematsu Y, Nishiyama K, Masaki N, et al. Treatment of carcinoma of the
uterine cervix by remotely controlled afterloading intracavitary radiotherapy
with high-dose-rate: a comparative study with a low-dose rate system. Int J
Radiat Oncol Biol Phys 1983; 9: 351-6.
113. Steel GG, Deacon JM, Duchesne GM, et al . The dose-rate effect in human
tumor cells. Radiother Oncol 1987; 9: 299-310
114. Strnad V, Geiger M, Lotter M, Sauer R. The role of pulsed dose rate BT in
previously irradiated head and neck cancer. BT 2003; 158-63
115. Strnad V, Melzner W, Geiger M, Zenk J, Waldfahrer F, Lotter M, Ott O Seeger
A, Iro H, Sauer R. Role of interstitial PDR BT in the treatment of oral and oro-
pharyngeal cancer. A single–institute experience of 236 patients.Strahlenther
Onkol. 2005; 181: 762-7
116. Swift PS, Purser P, Roberts LW, Pickett B, Powel CB, Phillips TL. Pulsed low
dose rate BT for pelvic malignancies. Int J Radiat Biol 1997; 37: 811-7.
117. Thames HD. An incomplete repair model for survival after fractionated and
continuous irradiation. Int J Radiat Biol 1985; 47: 319-39.
118. Thames HD, Bentzen SM, Tureson I, et al. Time-dose factors in radiotherapy:
a review of the human data. Radiother Oncol 1990; 19: 219-36.
119. Touboul E, Belkacemi Y, Lefranc J.P, Uzan S, Ozsahin M, Korbas D, et al.Early
breast cancer: influence of type of boost (electrons vs iridium-192 implant) on
local control and cosmesis after conservative surgery and radiation therapy.
Radiother Oncol, 34 (2) (1995), pp. 105–11
120. Turesson I, Thames HD. Repair capacity and kinetics of human skin during
fractionated radiotherapy: erythema, dequamation and telangiectasia after
3-year and 5-year follow-up. Radiother Oncol 1989; 15: 169-88.
121. Van Limbergen E, Chassagne D, Gerbaulet A, Haie C. Diferent dose rates
in preoperative endocurietherapy BT of cervical carcinoma. J Eur Radiother
1985; 6: 21-27.
122. Verhoeven K , Kindts I, Laenen A, Peeters S, Janssen H, Van Limber-
gen E, Weltens C. A comparison of three different radiotherapy boost tech-
niques after breast conserving therapy for breast cancer. The Breast 2015: 24
(4) 391-396.
123. Visser AG, van der Aardweg GJ, Levendag PC. Pulsed dose rate and fraction-
ated high dose rate BT: choice of BT schedule to replace low dose rate treat-
ments. Int J Radiat Oncol Biol Phys1996; 34: 497-505.
124. Wendt CD, Peters LJ, Delclos L, et al. Primary radiotherapy in the treatment
of Stage I and II oral tongue cancers: importance of the proportion of therapy
delivered with interstitial therapy. Int J Radiat Oncol Biol Phys1989: 18: 1287-
98.
125. Yarnold J, Ashton A, Bliss J, Homewood J,Harper C, Hanson J, Haviland J,
Bentzen S, Owen R. Fractionation sensitivity and dose response of late adverse
effects in the breast after radiotherapy for early breast cancer: long term results
of a randomised trial. Radiotherapy and Oncology 1994.
126. Withers HR. The four R’s of Radiobiology. Adv Radiol Biol 1975;5: 241-7
127. Wouters, B. G., Begg, A. C.Irradiation-induced damage and the DNA damage
responsein: Joiner, M., Van der Kogel, A. (Eds.) Basic Clinical Radiobiology,
4th Edition, Chapter 2; Hodder Arnold, London, 2009, 11-26
128. Zamboglou, N., Tselis, N., Baltas, D., Chatzikonstantinou, G., Kolotas, C.,
Milickovic, N., Chung, T.L., High-Dose-Rate Interstitial Brachytherapy as
Monotherapy for Clinically Localized Prostate Cancer: Treatment Evolution
and Mature Results. Int. J. Rad. Oncol. Biol. Phys.,85, No. 3, 672-678, 2013